<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00624585</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-15276</org_study_id>
    <secondary_id>CA180-106</secondary_id>
    <nct_id>NCT00624585</nct_id>
  </id_info>
  <brief_title>Study of Oral Dasatinib in Subjects With Myelodysplastic Syndrome (MDS) and Excess Marrow Blasts</brief_title>
  <official_title>A Pilot Study of Oral Dasatinib in Subjects With MDS and Excess Marrow Blasts</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to learn how patients with myelodysplastic syndrome (MDS)&#xD;
      respond to the study drug dasatinib. The study drug, dasatinib, has been approved by the U.S.&#xD;
      Food and Drug Administration (FDA) for treatment of leukemia, but has not been approved for&#xD;
      the treatment of other kinds of cancer. The use of dasatinib in this study is considered&#xD;
      experimental.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Core Period:&#xD;
&#xD;
      The first 16 weeks after the initial dose of dasatinib is called the Study Core Period.&#xD;
      Patients who are eligible and chose to participate in this study should expect to take 100 mg&#xD;
      of dasatinib daily for 8 weeks. If the study doctor believes that they have not achieved a&#xD;
      partial response after 8 weeks of treatment, the dose may be increased to 150 mg per day. The&#xD;
      study doctor may lower the dosage of dasatinib if the 100 mg treatment is too strong. If the&#xD;
      lower dose of dasatinib is still too strong, the study doctor may decide to take the patient&#xD;
      off of the study. The patient will continue to receive supportive care as needed during the&#xD;
      duration of the trial as well as after completion of the trial.&#xD;
&#xD;
      During the Study Core Period, participants will have a study visit every 4 weeks. Complete&#xD;
      Blood Counts (CBCs) will be obtained every 2 weeks for study purposes and disease monitoring.&#xD;
      Bone marrow aspiration and biopsy will be obtained at screening, and at 8 weeks and 16 weeks&#xD;
      of treatment for response assessment. Additional bone marrow aspirations and biopsies may be&#xD;
      obtained at any other time, to evaluate the disease process, at the doctor's judgment. A bone&#xD;
      marrow aspirate and biopsy must be done at the time of study discontinuation.&#xD;
&#xD;
      Study Extension Period:&#xD;
&#xD;
      The time after the first 16 weeks of treatment is called the study extension period. If the&#xD;
      patient is responding to the treatment, does not experience disease progression or any severe&#xD;
      adverse events, the patient may continue dasatinib treatment for up to 48 weeks. If patients&#xD;
      continue after 48 weeks, they will be asked to enroll in a separate extension study for&#xD;
      future follow up.&#xD;
&#xD;
      During the Study Extension Period, participants will have a study visit every 4 weeks.&#xD;
      Complete Blood Counts (CBCs) will be obtained every 2 or 4 weeks for study purposes and&#xD;
      disease monitoring. Bone marrow aspiration and biopsy will be obtained every 16 weeks. A bone&#xD;
      marrow aspirate and biopsy must be done at the time of study discontinuation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Marrow Complete Remission (CR)</measure>
    <time_frame>1 Year 4 Months</time_frame>
    <description>Complete remission (modified IWG); IWG = International MDS Working Group.&#xD;
Bone Marrow Response must last ≥4 weeks. Bone marrow evaluation: Bone marrow showing ≤5% myeloblasts with normal maturation of all cell lines.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Hematologic Improvement</measure>
    <time_frame>1 Year 4 Months</time_frame>
    <description>Hematologic improvement in platelets, red blood cell (RBC), neutrophils according to modified IWG Criteria; Cytogenetic response (modified IWG); Change in percentage of blasts in bone marrow and peripheral blood; Src-Tyr416 phosphorylation in medullary myeloblasts. Hematologic improvements must last ≥ 8 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Partial Remission (PR)</measure>
    <time_frame>1 Year 4 Months</time_frame>
    <description>Partial remission (PR) (modified IWG); IWG = International MDS Working Group. All of the CR criteria (if abnormal prior to treatment), except: Bone marrow evaluation: Blasts decreased by ≥ 50% over pretreatment but still &gt;5%. Cellularity and morphology are not relevant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Stable Disease (SD)</measure>
    <time_frame>1 Year 4 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>Dasatinib Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be started on dasatinib at a continuous oral daily dose of 100 mg per day. At 8 weeks, if the initial dose is well tolerated and patient has not achieved a partial response, the dose may be increased to 150 mg per day. All patients will be followed per protocol for a total core period of 16 weeks from the first dose. Responding patients will continue dasatinib treatment for up to 48 weeks in the absence of treatment failure, disease progression, limiting toxicity or death. Patients continuing after 48 weeks will be enrolled in a separate extension study for future follow up.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasatinib</intervention_name>
    <description>DOSE ESCALATION OF DASATINIB AFTER 8 WEEKS IF ELIGIBLE&#xD;
Dose Level and Dose of dasatinib:&#xD;
Starting dose (1-8 weeks)= 100 mg orally (po) daily&#xD;
+1 (&lt;8 weeks if no PR and well tolerated) = 150 mg po daily&#xD;
DOSE MODIFICATION OF DASATINIB&#xD;
Dose Level and Dose of dasatinib:&#xD;
Starting dose = 100 mg po daily&#xD;
-1 = 70 mg po daily&#xD;
-2 = 50 mg po daily&#xD;
OR&#xD;
Dose Level and Dose of dasatinib:&#xD;
Starting dose = 150 mg po daily&#xD;
-1 = 120 mg po daily&#xD;
-2 = 90 mg po daily&#xD;
-3 = 50 mg po daily</description>
    <arm_group_label>Dasatinib Dose Escalation</arm_group_label>
    <other_name>SPRYCEL®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Documented diagnosis of MDS or Myeloproliferative Disorders (MPS/MPD) with blast&#xD;
             percentage &gt; 10% in bone marrow, MDS/AML with &lt;30% blasts:&#xD;
&#xD;
               -  MDS [all World Health Organization (WHO) types] with blast percentage &gt; 10% in&#xD;
                  bone marrow&#xD;
&#xD;
               -  Chronic myelomonocytic leukemia (CMML) with blast percentage &gt; 10% in bone marrow&#xD;
&#xD;
               -  Myelodysplastic / Myeloproliferative (MDS/MPD) syndromes with blast percentage &gt;&#xD;
                  10% in bone marrow&#xD;
&#xD;
               -  Acute myeloid leukemia with Multilineage Dysplasia (MDS/AML) with &lt;30% blasts and&#xD;
                  declined standard induction chemotherapy or deemed unfit for standard induction&#xD;
                  chemotherapy&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 2&#xD;
&#xD;
          -  Previous therapy with Azacitidine or Decitabine with last dose at least 2 months prior&#xD;
             to first dose of dasatinib okay. Must be at least 4 weeks out from any previous&#xD;
             investigational therapy.&#xD;
&#xD;
          -  Adequate Organ Function&#xD;
&#xD;
               -  Total bilirubin &lt; 2.0 times institutional Upper Limit of Normal (ULN)&#xD;
&#xD;
               -  Hepatic enzymes (AST, ALT) ≤ 2.5 times institutional ULN&#xD;
&#xD;
               -  Serum Na, K+, Mg2+, Phosphate and Ca2+≥ Lower Limit of Normal (LLN) [low&#xD;
                  electrolyte levels must be repleted to all for entry]&#xD;
&#xD;
               -  Serum Creatinine &lt; 1.5 times ULN&#xD;
&#xD;
               -  Prothrombin time (PT), partial thromboplastin time (PTT) Grade 0-1&#xD;
&#xD;
          -  Able to take oral medication (Dasatinib must be swallowed whole. Tablets can be&#xD;
             dissolved in juice and then put down an NG/G tube or drank as a solution)&#xD;
&#xD;
          -  Women of childbearing potential (WOCBP) must have Negative serum or urine pregnancy&#xD;
             test within 72 hours prior to start of study drug&#xD;
&#xD;
          -  Persons of reproductive potential must agree to use adequate birth control throughout&#xD;
             treatment and at least 4 weeks after study drug is stopped&#xD;
&#xD;
          -  Signed written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  White blood count (WBC) &gt;50,000 off hydroxyurea for &gt;72 hours&#xD;
&#xD;
          -  Malignancy [other than the one treated in this study] requiring radiotherapy or&#xD;
             systemic treatment within past 3 years&#xD;
&#xD;
          -  Chemotherapy or any agent with activity in MDS or AML concurrent with the study.&#xD;
&#xD;
          -  Chemotherapy for MDS or AML prior to enrollment not allowed other than Azacitidine or&#xD;
             Decitabine &gt;2 months prior to first dose&#xD;
&#xD;
          -  Concurrent medical condition which may increase the risk of toxicity, including:&#xD;
&#xD;
               -  Pleural or pericardial effusion&#xD;
&#xD;
               -  Serious medical condition, unstable medical co-morbidity, psychiatric illness&#xD;
                  that will prevent subject from signing informed consent form or place them at&#xD;
                  unacceptable risk if they participate&#xD;
&#xD;
          -  Cardiac Symptoms, including:&#xD;
&#xD;
               -  Uncontrolled angina, congestive heart failure or myocardial infarction (MI)&#xD;
                  within 6 months&#xD;
&#xD;
               -  Diagnosed congenital long QT syndrome&#xD;
&#xD;
               -  History of clinically significant ventricular arrhythmias (such as ventricular&#xD;
                  tachycardia, ventricular fibrillation, or Torsades de Pointes)&#xD;
&#xD;
               -  Prolonged QTc interval on pre-entry electrocardiogram (&gt; 450 msec)&#xD;
&#xD;
          -  Hypokalemia or hypomagnesemia if cannot be corrected&#xD;
&#xD;
          -  History of significant bleeding disorder unrelated to cancer, including:&#xD;
&#xD;
               -  Congenital bleeding disorders&#xD;
&#xD;
               -  Acquired bleeding disorder within 1 year&#xD;
&#xD;
               -  Ongoing or recent (≤ 3 months) significant gastrointestinal bleeding&#xD;
&#xD;
          -  Concomitant Medications, consider the following prohibitions:&#xD;
&#xD;
               -  Drugs generally accepted to have risk of causing Torsades de Pointes(Must&#xD;
                  discontinue drug 7 days prior to starting dasatinib)&#xD;
&#xD;
               -  Concomitant use of H2 blockers or proton pump inhibitors with dasatinib not&#xD;
                  recommended. Use of antacids should be considered in place of H2 blockers or&#xD;
                  proton pump inhibitors in patients receiving dasatinib therapy.&#xD;
&#xD;
               -  On-going requirement for treatment with platelet function inhibitor or&#xD;
                  anti-coagulation.&#xD;
&#xD;
               -  Must discontinue St. Johns Wort while receiving dasatinib therapy&#xD;
&#xD;
               -  Must agree that intravenous (IV) bisphosphonates be withheld for first 8 weeks of&#xD;
                  Dasatinib therapy due to risk of hypocalcemia.&#xD;
&#xD;
               -  May not be receiving any prohibited CYP3A4 inhibitors&#xD;
&#xD;
          -  Women:&#xD;
&#xD;
               -  Positive pregnancy test at baseline&#xD;
&#xD;
               -  Pregnant or breastfeeding&#xD;
&#xD;
          -  Prisoners or patients who are compulsorily detained for treatment of either&#xD;
             psychiatric or physical (e.g., infectious) illness&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan List, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. Lee Moffitt Cancer Center and Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.moffitt.org/research--clinical-trials/clinical-trials</url>
    <description>Moffitt Cancer Center Clinical Trials website</description>
  </link>
  <verification_date>May 2012</verification_date>
  <study_first_submitted>February 15, 2008</study_first_submitted>
  <study_first_submitted_qc>February 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2008</study_first_posted>
  <results_first_submitted>May 23, 2012</results_first_submitted>
  <results_first_submitted_qc>May 23, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 25, 2012</results_first_posted>
  <last_update_submitted>November 21, 2013</last_update_submitted>
  <last_update_submitted_qc>November 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MDS</keyword>
  <keyword>MDS/MPD</keyword>
  <keyword>MDS/AML</keyword>
  <keyword>CMML</keyword>
  <keyword>Excess Marrow Blasts</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dasatinib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients with Int-2 or High risk MDS according to International Prognostic Scoring System (IPSS) score. All World Health Organization (WHO) subtypes of Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), or Myelodysplastic / Myeloproliferative (MDS/MPD) were allowed.</recruitment_details>
      <pre_assignment_details>Acute Myeloid Leukemia Multilineage Dysplasia (MDS/AML) with &lt;30% blasts (RAEB-t) who either declined or were deemed unfit for induction chemotherapy were also eligible. Exclusion criteria were WBC &gt;50,000 off hydroxyurea, another malignancy requiring radiation or chemotherapy within the past 3 years, or concurrent therapy for MDS or AML.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Dasatinib Dose Escalation</title>
          <description>Patients were started on dasatinib at a continuous oral daily dose of 100 mg per day. At 8 weeks, if the initial dose was well tolerated and patient had not achieved a partial response, the dose could be increased to 150 mg per day. All patients were followed per protocol for a total core period of 16 weeks from the first dose. Responding patients could continue dasatinib treatment for up to 48 weeks in the absence of treatment failure, disease progression, limiting toxicity or death. Patients continuing after 48 weeks will be enrolled in a separate extension study for future follow up.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dasatinib Dose Escalation</title>
          <description>Patients were started on dasatinib at a continuous oral daily dose of 100 mg per day. At 8 weeks, if the initial dose was well tolerated and patient had not achieved a partial response, the dose could be increased to 150 mg per day. All patients were followed per protocol for a total core period of 16 weeks from the first dose. Responding patients could continue dasatinib treatment for up to 48 weeks in the absence of treatment failure, disease progression, limiting toxicity or death. Patients continuing after 48 weeks will be enrolled in a separate extension study for future follow up.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.5" lower_limit="60" upper_limit="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Marrow Complete Remission (CR)</title>
        <description>Complete remission (modified IWG); IWG = International MDS Working Group.&#xD;
Bone Marrow Response must last ≥4 weeks. Bone marrow evaluation: Bone marrow showing ≤5% myeloblasts with normal maturation of all cell lines.</description>
        <time_frame>1 Year 4 Months</time_frame>
        <population>All Participants</population>
        <group_list>
          <group group_id="O1">
            <title>Dasatinib Dose Escalation</title>
            <description>Patients were started on dasatinib at a continuous oral daily dose of 100 mg per day. At 8 weeks, if the initial dose was well tolerated and patient had not achieved a partial response, the dose could be increased to 150 mg per day. All patients were followed per protocol for a total core period of 16 weeks from the first dose. Responding patients could continue dasatinib treatment for up to 48 weeks in the absence of treatment failure, disease progression, limiting toxicity or death. Patients continuing after 48 weeks will be enrolled in a separate extension study for future follow up.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Marrow Complete Remission (CR)</title>
          <description>Complete remission (modified IWG); IWG = International MDS Working Group.&#xD;
Bone Marrow Response must last ≥4 weeks. Bone marrow evaluation: Bone marrow showing ≤5% myeloblasts with normal maturation of all cell lines.</description>
          <population>All Participants</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Hematologic Improvement</title>
        <description>Hematologic improvement in platelets, red blood cell (RBC), neutrophils according to modified IWG Criteria; Cytogenetic response (modified IWG); Change in percentage of blasts in bone marrow and peripheral blood; Src-Tyr416 phosphorylation in medullary myeloblasts. Hematologic improvements must last ≥ 8 weeks.</description>
        <time_frame>1 Year 4 Months</time_frame>
        <population>All Participants</population>
        <group_list>
          <group group_id="O1">
            <title>Dasatinib Dose Escalation</title>
            <description>Patients were started on dasatinib at a continuous oral daily dose of 100 mg per day. At 8 weeks, if the initial dose was well tolerated and patient had not achieved a partial response, the dose could be increased to 150 mg per day. All patients were followed per protocol for a total core period of 16 weeks from the first dose. Responding patients could continue dasatinib treatment for up to 48 weeks in the absence of treatment failure, disease progression, limiting toxicity or death. Patients continuing after 48 weeks will be enrolled in a separate extension study for future follow up.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hematologic Improvement</title>
          <description>Hematologic improvement in platelets, red blood cell (RBC), neutrophils according to modified IWG Criteria; Cytogenetic response (modified IWG); Change in percentage of blasts in bone marrow and peripheral blood; Src-Tyr416 phosphorylation in medullary myeloblasts. Hematologic improvements must last ≥ 8 weeks.</description>
          <population>All Participants</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Partial Remission (PR)</title>
        <description>Partial remission (PR) (modified IWG); IWG = International MDS Working Group. All of the CR criteria (if abnormal prior to treatment), except: Bone marrow evaluation: Blasts decreased by ≥ 50% over pretreatment but still &gt;5%. Cellularity and morphology are not relevant.</description>
        <time_frame>1 Year 4 Months</time_frame>
        <population>All Participants</population>
        <group_list>
          <group group_id="O1">
            <title>Dasatinib Dose Escalation</title>
            <description>Patients were started on dasatinib at a continuous oral daily dose of 100 mg per day. At 8 weeks, if the initial dose was well tolerated and patient had not achieved a partial response, the dose could be increased to 150 mg per day. All patients were followed per protocol for a total core period of 16 weeks from the first dose. Responding patients could continue dasatinib treatment for up to 48 weeks in the absence of treatment failure, disease progression, limiting toxicity or death. Patients continuing after 48 weeks will be enrolled in a separate extension study for future follow up.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Partial Remission (PR)</title>
          <description>Partial remission (PR) (modified IWG); IWG = International MDS Working Group. All of the CR criteria (if abnormal prior to treatment), except: Bone marrow evaluation: Blasts decreased by ≥ 50% over pretreatment but still &gt;5%. Cellularity and morphology are not relevant.</description>
          <population>All Participants</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Stable Disease (SD)</title>
        <time_frame>1 Year 4 Months</time_frame>
        <population>All Participants</population>
        <group_list>
          <group group_id="O1">
            <title>Dasatinib Dose Escalation</title>
            <description>Patients were started on dasatinib at a continuous oral daily dose of 100 mg per day. At 8 weeks, if the initial dose was well tolerated and patient had not achieved a partial response, the dose could be increased to 150 mg per day. All patients were followed per protocol for a total core period of 16 weeks from the first dose. Responding patients could continue dasatinib treatment for up to 48 weeks in the absence of treatment failure, disease progression, limiting toxicity or death. Patients continuing after 48 weeks will be enrolled in a separate extension study for future follow up.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Stable Disease (SD)</title>
          <population>All Participants</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 Year 4 Months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Dasatinib Dose Escalation</title>
          <description>Patients were started on dasatinib at a continuous oral daily dose of 100 mg per day. At 8 weeks, if the initial dose was well tolerated and patient had not achieved a partial response, the dose could be increased to 150 mg per day. All patients were followed per protocol for a total core period of 16 weeks from the first dose. Responding patients could continue dasatinib treatment for up to 48 weeks in the absence of treatment failure, disease progression, limiting toxicity or death. Patients continuing after 48 weeks will be enrolled in a separate extension study for future follow up.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTC V3</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood/Bone Marrow - Grade 4</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Edema: limb - Grade 2</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hemoglobin - Grade 3 - *Possibly related</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hemoglobin - Grade 4 - *Possibly related</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Platelets - Grade 3 - *Possibly related</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Platelets - Grade 4 - *Possibly related</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac general - Grade 3</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypertension - Grade 3</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia - Grade 3 - *Possibly related</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dehydration - Grade 3</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Diarrhea - Grade 1</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Diarrhea - Grade 3 - *Possibly related</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis (oral cavity) - Grade 3</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Nausea - Grade 2</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Nausea - Grade 3 - *Possibly related</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Vomiting - Grade 1</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Vomiting - Grade 2</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Vomiting - Grade 3 - *Possibly related</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue - Grade 3 - *Possibly related</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Fever in absence of neutropenia - Grade 2</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hematoma - Grade 1</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI - Lower GI NOS - Grade 3</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI - Rectum - Grade 3 - *Possibly related</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI - Upper GI - Grade 3 - *Possibly related</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pain - Cardiac/heart - Grade 3</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pain - head/headache - Grade 3</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pain: abdomen - Grade 2</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis - Grade 3 - *Possibly related</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hepatobiliary/Pancreas - Grade 1</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia - Grade 3</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia - Grade 3 - *Possibly related</sub_title>
                <description>*&quot;Possibly related to study&quot; events are noted as appropriate</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Infection - Grade 3</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Infection - Grade 3 - *Possibly related</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Lung - Grade 3</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - lung - Grade 3 - *Possibly related</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Glucose, serum - low - Grade 4</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion - Grade 3</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure - Grade 3</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Renal failure - Grade 3 - *Possibly related</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Renal/Genitourinary - Grade 2</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea - Grade 2</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dyspnea - Grade 2 - *Possibly related</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dyspnea - Grade 3</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dyspnea - Grade 3 - **Definitely related</sub_title>
                <description>**&quot;Definitely related to study&quot; events are noted as appropriate</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dyspnea - Grade 3 - *Possibly related</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pleural effusion - Grade 2 - **Definitely related</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pleural effusion - Grade 2 - *Possibly related</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pleural effusion - Grade 3 - *Possibly related</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTC V3</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood/Bone Marrow - *Possibly related</sub_title>
                <description>*&quot;Possibly related to study&quot; events are noted as appropriate</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Edema: limb - *3 Events possbily related</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hemoglobin - *11 Events possibly related</sub_title>
                <counts group_id="E1" events="12" subjects_affected="6" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Iron overload</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Leukocytes (total WBC) - *Possibly related</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Lymphatics</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC) - *Possibly related</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Platelets - *6 Events possibly related</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac troponia I (cTnl)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Supraventricular and nodal arrhythmia - Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Auditory/Ear</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular/Visual - *1 Event possibly related</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia - *2 Events possibly related</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Constipation - *3 Events possibly related</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dehydration - *Possibly related</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Diarrhea - *5 Events possibly related</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dysgeusia - *4 Events possibly related</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Gastrointestinal - other - *3 Events possibly related</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Heartburn/dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis - Oral cavity - *Possibly related</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Nausea - *Possibly related</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Vomiting - *Possibly related</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Fatigue - *13 Events possibly related</sub_title>
                <counts group_id="E1" events="20" subjects_affected="12" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI - Oral cavity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI - Rectum - *1 Event possibly related</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hemorrhage, pulmonary/upper respiratory - Lung - *Possibly related</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pain - Abdomen - *2 Events possibly related</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pain - Back</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pain - Breast</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pain - Chest wall - *1 Event possibly related</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pain - Extremity: limb</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pain - Head/headache - *4 Events possibly related</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pain - Joint - *Possibly related</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pain - Oral cavity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pain - Throat/pharynx/larynx - *1 Event possibly related</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Rigors/chills - *1 Event possibly related</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Sweating (diaphoresis) - *1 Event possibly related</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Weight loss - *Possibly related</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Alergic rhinitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia - *3 Events possibly related</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Infection - other - *2 Events possibly related</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Infection with Grade 3 or 4 neutrophils - Urinary tract - *Possibly related</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Infection with Grade 3 or 4 neutrophils - Skin - *Possibly related</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Sinus - *1 Event possibly related</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Calcium, serum-high (hypercalcemia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Glucose, serum-high (hyperglycemia)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Potassium, serum-low (hypokalemia) - *1 Event possibly related</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle weakness - *2 Events possibly related</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Neuropathy - *Possibly related</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mood alteration - Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure - *Possibly related</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Urinary frequency/urgency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough - *3 Events possibly related</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dyspnea - *6 Events possibly related</sub_title>
                <counts group_id="E1" events="14" subjects_affected="8" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypoxia - *Possibly related</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pleural effusion - *Possibly related</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pulmonary/Upper Respiratory - other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bruising (in absence of Grade 3 or 4 thrombocytopenia) - *2 Events possibly related</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dermatology</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Flushing - *Possibly related</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hair loss/alopecia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pruritus/itching</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Rash/desquamation - *Possibly related</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Rash: acne/acneiform</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Rash: hand-foot skin reaction - *Possibly related</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Ulceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alan F. List, Executive Vice President &amp; President, Moffitt Medical Group</name_or_title>
      <organization>H. Lee Moffitt Cancer Center and Research Institute</organization>
      <phone>813-745-6086</phone>
      <email>alan.list@moffitt.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

